This course is FREE with Unlimited CE!

Choose from two Unlimited CE subscription options and get access to 600+ CE and professional development courses.

Get access starting at $49.95/yrLoading..

Goals and Learning Outcomes

As many as one in four people with cancer will experience depression during or after their treatment course. The effects of depression can impact the patient’s psychosocial well-being and disease outcomes. Depression is associated with poor treatment adherence, decreased quality of life, poor sleep, increased healthcare spending, increased suicide rates, and increased mortality. Although depression is a recognized problem in people with cancer, it is undetected by healthcare providers in up to 50% of cases.

The goal of this course is to provide nurses, physicians, dietitians, radiologic technologists, and pharmacists in the acute care setting with information about the occurrence of depression in people with cancer, including a review of symptoms, special considerations for patients undergoing treatment, screening tools, and available treatments.

This course has a maximum of 3 exam attempts.

After taking this course, you should be able to:

  • Indicate two reasons that depression is underdiagnosed and undertreated in patients with cancer
  • Identify three potential negative effects of depression on the well-being of a patient with cancer
  • Describe three interprofessional interventions that can be recommended for patients with cancer who are experiencing depression
  • Determine signs, symptoms, and risk factors related to depression among people with cancer.
  • Identify the recommendations for screening for distress and depressive symptoms among people with cancer.
  • Identify the structure and benefits of an interprofessional team approach to cancer care and recognize at least three interprofessional interventions and how they are used among people with cancer who are experiencing depression.

Course Termination Date: Not yet determined

Content Expiration Date: 12/31/24

Course Originally Released On: 05/01/21

Course Authors

4.4 Average

Course Reviews

7568 reviews

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, Kansas State Board of Nursing, Kentucky Board of Nursing, Michigan Board of Nursing, Mississippi Board of Nursing, New Hampshire Board of Nursing, New Mexico Board Of Nursing, North Dakota Board of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Registered Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.